Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer

verfasst von: A. Mansour, M. Nabil, R. Ali-Labib, H. Said, F. Annos

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

There is an intimate relation between disturbance in survivin and SMAC/DIABLO expressions and cancer formation in many tissues; however, this was not confirmed in the primary breast cancer. The aim of this study was to evaluate the relationship between survivin and SMAC/DIABLO mRNA expressions in primary breast cancer using RT-PCR and their relationship to some of the risk factors (age, family history, breast-feeding, use of contraceptive pills and hormonal receptors). Breast cancer tissues were studied for the detection of the mRNA expression of survivin and SMAC/DIABLO. This was done by qualitative reverse transcription–polymerase chain reaction (RT-PCR). SMAC/DIABLO mRNA was detected by RT-PCR only in 1 sample in breast cancer tissues (6.25%). However, it was expressed in 16 out of 25 (64%) of the benign tumor tissues (P = 0.00). In contrast, survivin mRNA was highly expressed in breast cancer tissues, 36 out of 48 (75%) (P = 0.00), while its expression was very low in benign tumor tissues, only 1 out of 37 (2.7%) (P = 0.00). Expressions of SMAC/DIABLO and survivin were significantly reciprocal in breast cancer and benign tumor tissues. SMAC/DIABLO inhibits apoptosis of breast cancer cells by suppression of survivin. These two genes probably form an important link in the signaling pathway of formation of breast cancer cells, which may be chosen as therapeutic targets in the primary breast cancer.
Literatur
2.
Zurück zum Zitat Abbas H, Elyamany A, Salem M, Salem A, Binzaid S, Gamal B. The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med. 2011;4(1):35.PubMedCrossRef Abbas H, Elyamany A, Salem M, Salem A, Binzaid S, Gamal B. The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med. 2011;4(1):35.PubMedCrossRef
3.
Zurück zum Zitat Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev. 2005;29:419–26.PubMedCrossRef Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev. 2005;29:419–26.PubMedCrossRef
4.
6.
Zurück zum Zitat Song Z, Yao X, Wu M. Direct interaction between Survivin and SMAC/DIABLO is essential for the anti-apoptotic activity of Survivin during taxol-induced apoptosis. J Biol Chem. 2003;278:23130–40.PubMedCrossRef Song Z, Yao X, Wu M. Direct interaction between Survivin and SMAC/DIABLO is essential for the anti-apoptotic activity of Survivin during taxol-induced apoptosis. J Biol Chem. 2003;278:23130–40.PubMedCrossRef
8.
Zurück zum Zitat Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.PubMedCrossRef Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.PubMedCrossRef
9.
Zurück zum Zitat Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of SMAC/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 2001;20:6627–36.PubMedCrossRef Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of SMAC/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 2001;20:6627–36.PubMedCrossRef
10.
Zurück zum Zitat Keane RW, Kraydieh S, Lotocki G, Alonso OF, Aldana P, Dietrich WD. Apoptotic and antiapoptotic mechanisms after traumatic brain injury. J Cereb Blood Flow Metab. 2001;21:1189–98.PubMedCrossRef Keane RW, Kraydieh S, Lotocki G, Alonso OF, Aldana P, Dietrich WD. Apoptotic and antiapoptotic mechanisms after traumatic brain injury. J Cereb Blood Flow Metab. 2001;21:1189–98.PubMedCrossRef
11.
Zurück zum Zitat Sugawara T, Noshita N, Lewen A, Gasche Y, Ferrand-Drake M, Fujimura M, et al. Overexpression of copper/zinc superoxide dismutase in transgenic rats protects vulnerable neurons against ischemic damage by blocking the mitochondrial pathway of caspase activation. J Neurosci. 2002;22:209–17.PubMed Sugawara T, Noshita N, Lewen A, Gasche Y, Ferrand-Drake M, Fujimura M, et al. Overexpression of copper/zinc superoxide dismutase in transgenic rats protects vulnerable neurons against ischemic damage by blocking the mitochondrial pathway of caspase activation. J Neurosci. 2002;22:209–17.PubMed
12.
Zurück zum Zitat Saito A, Hayashi T, Okuno S, Ferrand-Drake M, Chan PH. Interaction between XIAP and SMAC/DIABLO in the mouse brain after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2003;23:1010–9.PubMedCrossRef Saito A, Hayashi T, Okuno S, Ferrand-Drake M, Chan PH. Interaction between XIAP and SMAC/DIABLO in the mouse brain after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2003;23:1010–9.PubMedCrossRef
13.
Zurück zum Zitat Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242–51.PubMedCrossRef Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999;18:5242–51.PubMedCrossRef
14.
Zurück zum Zitat Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem. 2002;277:439–44.PubMedCrossRef Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem. 2002;277:439–44.PubMedCrossRef
15.
Zurück zum Zitat Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685–94.PubMed Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685–94.PubMed
16.
Zurück zum Zitat Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998;273:7787–90.PubMedCrossRef Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998;273:7787–90.PubMedCrossRef
17.
Zurück zum Zitat Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and SMAC/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410:112–6.PubMedCrossRef Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and SMAC/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410:112–6.PubMedCrossRef
18.
Zurück zum Zitat Salako SE. The declaration of Helsinki 2000: ethical principles and the dignity of difference. Med Law. 2006;25(2):341–54.PubMed Salako SE. The declaration of Helsinki 2000: ethical principles and the dignity of difference. Med Law. 2006;25(2):341–54.PubMed
19.
Zurück zum Zitat Discovery Studio Gene v1.5 from Accelrys primer designing program, USA. 2007. Discovery Studio Gene v1.5 from Accelrys primer designing program, USA. 2007.
20.
Zurück zum Zitat Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Büttner R, Schölmerich J, Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996–1005. doi:10.1038/cr.2009.73.PubMedCrossRef Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Büttner R, Schölmerich J, Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996–1005. doi:10.​1038/​cr.​2009.​73.PubMedCrossRef
21.
Zurück zum Zitat DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011;20(5):733–9.PubMedCrossRef DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev. 2011;20(5):733–9.PubMedCrossRef
22.
Zurück zum Zitat Ijaduola TG, Smith EB. Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc. 1998;90(9):547–51.PubMed Ijaduola TG, Smith EB. Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc. 1998;90(9):547–51.PubMed
23.
Zurück zum Zitat Vorobiof DA, Sitas F, Vorobiof G. Breast cancer incidence in South Africa. J Clin Oncol. 2001;19(18):125S–7S.PubMed Vorobiof DA, Sitas F, Vorobiof G. Breast cancer incidence in South Africa. J Clin Oncol. 2001;19(18):125S–7S.PubMed
24.
Zurück zum Zitat Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2002;7:910–8.CrossRef Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2002;7:910–8.CrossRef
25.
Zurück zum Zitat Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66(4):283–92.PubMed Lambrechts S, Decloedt J, Neven P. Breast cancer prevention: lifestyle changes and chemoprevention. Acta Clin Belg. 2011;66(4):283–92.PubMed
26.
Zurück zum Zitat Freudenheim JL, Marshall JR, Vena JE. Lactation history and breast cancer risk. Am J Epidemiol. 1997;146:932–8.PubMedCrossRef Freudenheim JL, Marshall JR, Vena JE. Lactation history and breast cancer risk. Am J Epidemiol. 1997;146:932–8.PubMedCrossRef
27.
Zurück zum Zitat Furberg H, Newman B, Moorman P, Millikan R. Lactation and breast cancer risk. Int J Epidemiol. 1999;28:396–402.PubMedCrossRef Furberg H, Newman B, Moorman P, Millikan R. Lactation and breast cancer risk. Int J Epidemiol. 1999;28:396–402.PubMedCrossRef
28.
Zurück zum Zitat Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, Boyle P, Zahm SH. Lactation and breast cancer risk: a case–control study in Connecticut. Br J Cancer. 2001;84(11):1472–6.PubMedCrossRef Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, Boyle P, Zahm SH. Lactation and breast cancer risk: a case–control study in Connecticut. Br J Cancer. 2001;84(11):1472–6.PubMedCrossRef
29.
Zurück zum Zitat Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025–32.PubMedCrossRef Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025–32.PubMedCrossRef
30.
Zurück zum Zitat Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4):S5–22.PubMedCrossRef Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4):S5–22.PubMedCrossRef
31.
Zurück zum Zitat Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17(7):2100–4.PubMed Monzo M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17(7):2100–4.PubMed
32.
Zurück zum Zitat Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer, molecular diagnostics. Br J Cancer. 2004;92:120–4.CrossRef Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill ADK, McDermott E, O’Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer, molecular diagnostics. Br J Cancer. 2004;92:120–4.CrossRef
33.
Zurück zum Zitat O`Driscoll L, Linhan R, Kennedybc M, Cronina D, Purcellbc R, Glynna S, McDermottd EW, Hilld AD, O’Higginsd NJ, Parkinsone M, Clynesa M. Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett. 2003;201:225–36.CrossRef O`Driscoll L, Linhan R, Kennedybc M, Cronina D, Purcellbc R, Glynna S, McDermottd EW, Hilld AD, O’Higginsd NJ, Parkinsone M, Clynesa M. Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett. 2003;201:225–36.CrossRef
34.
Zurück zum Zitat Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6(1):127–34.PubMed Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6(1):127–34.PubMed
35.
Zurück zum Zitat Kennedy SM, O’Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O’Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077–83.PubMedCrossRef Kennedy SM, O’Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O’Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077–83.PubMedCrossRef
36.
Zurück zum Zitat Riedl SJ, Renatus M, Schvanzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791–800.PubMedCrossRef Riedl SJ, Renatus M, Schvanzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104:791–800.PubMedCrossRef
37.
Zurück zum Zitat Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of SMAC/DIABLO and its role in the death receptor pathway. J Biol Chem. 2000;275:36152–7.PubMedCrossRef Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of SMAC/DIABLO and its role in the death receptor pathway. J Biol Chem. 2000;275:36152–7.PubMedCrossRef
38.
Zurück zum Zitat Huang Y, Park YC, Rich RL, Segal D, Myszak DG, Wu H. Structural basis of caspase inhibition by XIAP; differential role of linker versus the BIR domain. Cell. 2001;104:781–90.PubMed Huang Y, Park YC, Rich RL, Segal D, Myszak DG, Wu H. Structural basis of caspase inhibition by XIAP; differential role of linker versus the BIR domain. Cell. 2001;104:781–90.PubMed
39.
Zurück zum Zitat Kashkar H, Haefs C. XIAP-mediated caspase inhibition in Hodgkin’s lymphoma-derived B cells. J Exp Med. 2003;198:341–7.PubMedCrossRef Kashkar H, Haefs C. XIAP-mediated caspase inhibition in Hodgkin’s lymphoma-derived B cells. J Exp Med. 2003;198:341–7.PubMedCrossRef
40.
Zurück zum Zitat Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, et al. JNK-dependent release of mitochondrial protein, SMAC, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003;278:17593–6.PubMedCrossRef Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, et al. JNK-dependent release of mitochondrial protein, SMAC, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003;278:17593–6.PubMedCrossRef
41.
Zurück zum Zitat Yoo NJ, Kim HS, Kim SY. Immunohistochemical analysis of SMAC/DIABLO expression in human carcinomas and sarcomas. APMIS. 2003;111:382–8.PubMedCrossRef Yoo NJ, Kim HS, Kim SY. Immunohistochemical analysis of SMAC/DIABLO expression in human carcinomas and sarcomas. APMIS. 2003;111:382–8.PubMedCrossRef
42.
Zurück zum Zitat Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–3.PubMedCrossRef Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–3.PubMedCrossRef
43.
Zurück zum Zitat Ryan B, Konecny E, Kahlert S, Wang J, Untch M, Meng G, Pegram M, Podratz K, Crown J, Salmon D, Duffy M. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:597–604.PubMedCrossRef Ryan B, Konecny E, Kahlert S, Wang J, Untch M, Meng G, Pegram M, Podratz K, Crown J, Salmon D, Duffy M. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:597–604.PubMedCrossRef
44.
Zurück zum Zitat Zhao JM, Zhu ZH, Wu QL, Hou JH, Huang XP, Zhang PY, Rong TH. Expression of Smac in stage I-II non-small cell lung cancer and its clinical significance. Ai Zheng. 2006;25(5):631–4.PubMed Zhao JM, Zhu ZH, Wu QL, Hou JH, Huang XP, Zhang PY, Rong TH. Expression of Smac in stage I-II non-small cell lung cancer and its clinical significance. Ai Zheng. 2006;25(5):631–4.PubMed
45.
Zurück zum Zitat Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor—negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008;68(13):5273–81.PubMedCrossRef Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor—negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008;68(13):5273–81.PubMedCrossRef
46.
Zurück zum Zitat Xie W, Jiang P, Miao L, Zhao Y, Zhimin Z, Qing L, Zhu WG, Wu M. Proapoptotic SMAC/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res. 2006;34(7):2046–55.PubMedCrossRef Xie W, Jiang P, Miao L, Zhao Y, Zhimin Z, Qing L, Zhu WG, Wu M. Proapoptotic SMAC/DIABLO is transcriptionally upregulated by E2F1. Nucleic Acids Res. 2006;34(7):2046–55.PubMedCrossRef
47.
Zurück zum Zitat Neubauer NL, Ward EC, Patel P, Lu Z, Lee I, Blok LJ, Hanifi-Moghaddam P, Schink J, Kim JJ. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis. Horm Cancer. 2011;2(3):170–81. doi:10.1007/s12672-011-0065-7.PubMedCrossRef Neubauer NL, Ward EC, Patel P, Lu Z, Lee I, Blok LJ, Hanifi-Moghaddam P, Schink J, Kim JJ. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis. Horm Cancer. 2011;2(3):170–81. doi:10.​1007/​s12672-011-0065-7.PubMedCrossRef
48.
Zurück zum Zitat Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724–32.PubMedCrossRef Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297(7):724–32.PubMedCrossRef
49.
Zurück zum Zitat Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY. Expression of surviving and clinical correlation in patients with breast cancer. Biomed Pharmacother. 2006;60(6):289–92.PubMedCrossRef Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY. Expression of surviving and clinical correlation in patients with breast cancer. Biomed Pharmacother. 2006;60(6):289–92.PubMedCrossRef
Metadaten
Titel
Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer
verfasst von
A. Mansour
M. Nabil
R. Ali-Labib
H. Said
F. Annos
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0129-0

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.